Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
KZIA 
Kazia Therapeutics Ltd ADR (KZIA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: KZIA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16.46
1 Year Target Price $16.46
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.11% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.06M USD | Price to earnings Ratio - | 1Y Target Price 16.46 |
Price to earnings Ratio - | 1Y Target Price 16.46 | ||
Volume (30-day avg) 1 | Beta 2.15 | 52 Weeks Range 2.86 - 39.05 | Updated Date 10/15/2025 |
52 Weeks Range 2.86 - 39.05 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -29.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -42029.54% |
Management Effectiveness
Return on Assets (TTM) -85.55% | Return on Equity (TTM) -3891.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8607340 | Price to Sales(TTM) 4.82 |
Enterprise Value 8607340 | Price to Sales(TTM) 4.82 | ||
Enterprise Value to Revenue 5.64 | Enterprise Value to EBITDA -0.71 | Shares Outstanding 1670577 | Shares Floating 422580635 |
Shares Outstanding 1670577 | Shares Floating 422580635 | ||
Percent Insiders 8.48 | Percent Institutions 10.65 |
Upturn AI SWOT
Kazia Therapeutics Ltd ADR
Company Overview
History and Background
Kazia Therapeutics Ltd (formerly Novogen Ltd) is an Australian oncology-focused pharmaceutical company, founded in 1993. Initially focused on cancer prevention, it shifted towards developing treatments for cancer and related conditions. Kazia is now focused on developing novel therapies for cancers.
Core Business Areas
- Pharmaceutical Development: Focuses on the research and development of novel anti-cancer drugs. Their two core areas of focus are Paxalisib for glioblastoma and EVT801 for various cancers.
Leadership and Structure
Kazia Therapeutics is led by Dr. James Garner (CEO). The organizational structure involves a management team overseeing research, development, and commercialization activities, with a board of directors providing strategic oversight.
Top Products and Market Share
Key Offerings
- Paxalisib: A PI3K/Akt/mTOR pathway inhibitor in clinical development for glioblastoma, an aggressive form of brain cancer. Market share is currently negligible due to it still in clinical trials, with competitors being standard of care chemotherapy, radiation, and surgery. Competitors include Merck (Temodar), Roche (Avastin), and various companies developing novel glioblastoma therapies.
- EVT801: A small molecule tyrosine kinase inhibitor targeting VEGFR3. It is in clinical development for advanced solid tumors. Market share is currently negligible due to it still in clinical trials. Competitors include large pharmaceutical companies developing similar targeted therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in oncology, is characterized by high R&D costs, stringent regulatory requirements, and intense competition. There is growing demand for targeted therapies and personalized medicine.
Positioning
Kazia Therapeutics is a smaller biotech company focused on developing innovative therapies for cancers with unmet medical needs. Its competitive advantage lies in its targeted therapies and focus on specific oncology indications.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Kazia is positioned to capture a segment of this market with its targeted therapies, particularly in glioblastoma, if Paxalisib is approved. Exact TAM depends on trial outcomes and regulatory approval.
Upturn SWOT Analysis
Strengths
- Innovative drug candidates (Paxalisib and EVT801)
- Targeted therapies for cancers with unmet needs
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High dependence on clinical trial outcomes
- Reliance on regulatory approvals
- Lack of commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new oncology indications
- Positive clinical trial results
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory rejections
- Competition from established therapies
- Patent infringement challenges
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- RHHBY
- BMY
- NVS
Competitive Landscape
Kazia faces intense competition from large pharmaceutical companies with significantly greater resources. Its success depends on the differentiation and efficacy of its targeted therapies. Advantages include its focus on unmet medical needs and innovative drug candidates. Disadvantages include limited financial resources and lack of commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by the advancement of its drug candidates through clinical trials.
Future Projections: Future growth is dependent on the successful completion of clinical trials for Paxalisib and EVT801, as well as potential partnerships and regulatory approvals. Analyst estimates are variable given the uncertainty.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Paxalisib and EVT801, as well as presentations at scientific conferences and investor relations activities.
Summary
Kazia Therapeutics is a development-stage biotech company with promising oncology assets, particularly Paxalisib. Its success hinges on positive clinical trial outcomes and regulatory approvals. The company faces considerable risk due to its dependence on clinical trial success and competition from larger pharmaceutical companies. Securing partnerships and managing cash burn will be critical for its long-term viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Kazia Therapeutics Ltd website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment in biotech companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kazia Therapeutics Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 1999-01-06 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | |
Full time employees - | |||
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.